Lung P01 Competing (1/25/17) Project 2 (Rosen, PI) ABSTRACT This project is focused on the development of effective therapies for lung tumors driven by activation of the ERK signaling pathway, particularly those in which the pathway is driven by mutations in the KRAS or BRAF proto-oncogenes. These tumors are particularly difficult to treat, in part because there are no direct inhibitors of mutant KRAS or of dimer-dependent non-V600 BRAF mutations or fusions; in part because of adaptive resistance to RAF or MEK inhibitors, which is mediated by relief of ERK dependent feedback; in part because BRAF V600 tumors develop acquired resistance; and because of the toxicity of MEK inhibitors. In the last funding period we made material progress in overcoming these obstacles. We discovered that BRAF mutants fall into three functional classes based on their mechanism of activation; developed specific mechanism-based methods of inhibition of each class of mutant; identified novel equipotent inhibitors of RAF monomers and dimers for the treatment of Class 1 and 2 RAF mutants; identified MEK inhibitors with an enhanced ability to inhibit MEK driven by mutant RAS; and characterized and determined the mechanism of action of direct inhibitors of KRAS G12C, the most common mutant RAS allele in lung cancer. The goal of the proposal is to use these inhibitors to understand the role of each of these oncoproteins in lung cancer and pursue their preclinical development.
Aim 1 concerns the use of the RAF dimer/monomer inhibitor to understand the role of Class 2 dimer-dependent BRAF mutants and to develop treatment regimens for Class 1 and 2 mutants.
Aim 2 concerns the study of Class 3 BRAF mutants, the most common class in lung cancer, and exploits a novel mechanism for inhibiting their activity.
Aim 3 concerns the preclinical development of the KRAS G12C inhibitor and its use to study the functional role of mutant RAS in lung cancer and the consequences of its inhibition. Inhibiting ERK signaling driven by any of the mutants is expected to relieve ERK-dependent feedback inhibition of signaling and contribute to adaptive resistance. In collaboration with RP4, we will undertake the study of this process for each of these methods of inhibiting RAS/RAF/MEK signaling, attempt to identify pathways required for tumor cell survival, and develop combination therapy on this basis.

Public Health Relevance

Lung P01 Competing (1/25/17) Project 2 (Rosen, PI) PROJECT NARRATIVE The project proposes to develop effective regimens for the treatment of tumors dependent on dysregulation of the ERK pathway by mutant KRAS or BRAF. We have discovered three classes of BRAF mutants and developed specific regimens for the pharmacologic inhibition of each, as well as an allele-specific inhibitor of mutant KRAS G12C. We will use these regimens to understand the role of each of these mutants in lung cancer and pursue their development as therapeutics.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Mo, Qianxing; Shen, Ronglai; Guo, Cui et al. (2018) A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data. Biostatistics 19:71-86
Childress, Merrida A; Himmelberg, Stephen M; Chen, Huiqin et al. (2018) ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties. Mol Cancer Res 16:1724-1736
Gao, Yijun; Chang, Matthew T; McKay, Daniel et al. (2018) Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discov 8:648-661
Arbour, Kathryn C; Jordan, Emmett; Kim, Hyunjae Ryan et al. (2018) Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res 24:334-340
Gallant, Jean-Nicolas; Lovly, Christine M (2018) Established, emerging and elusive molecular targets in the treatment of lung cancer. J Pathol 244:565-577
Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4
Yao, Zhan; Gao, Yijun; Su, Wenjing et al. (2018) RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med :
Suzawa, Ken; Offin, Michael; Lu, Daniel et al. (2018) Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res :
Yu, Helena A; Planchard, David; Lovly, Christine M (2018) Sequencing Therapy for Genetically Defined Subgroups of Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book :726-739
Yuan, Tina L; Amzallag, Arnaud; Bagni, Rachel et al. (2018) Differential Effector Engagement by Oncogenic KRAS. Cell Rep 22:1889-1902

Showing the most recent 10 out of 188 publications